Predictions [46]
All tags
aerospace-defense
auto-ev
cloud
consumer-internet
ecommerce
energy
fintech
gaming
media
payments
pharma
retail
saas
security
semis
| Confidence | Ticker | Claim | Target | Tags |
|---|---|---|---|---|
| 95% |
PF
PFE |
Pfizer will continue quarterly earnings disclosures. | 37d | pharma |
| 95% |
JN
JNJ |
J&J will disclose additional details on the talc settlement in Q3 earnings. | 8d | pharma |
| 95% |
JN
JNJ |
J&J will report Q3 2026 financial results, including initial impact of the talc settlement and Imaavy's approval. | 18d | pharma |
| 90% |
JN
JNJ |
J&J will finalize talc settlement disbursements and report associated financial impacts. | 130d | pharma |
| 90% |
JN
JNJ |
Johnson & Johnson will file additional SEC 8-Ks related to legal matters within the next month. | grading due | pharma |
| 90% |
PF
PFE |
Pfizer will announce Q3 results and update guidance. | 18d | pharma |
| 90% |
PF
PFE |
Pfizer will report Q3 2026 earnings, likely detailing new product contributions. | 38d | pharma |
| 90% |
JN
JNJ |
J&J will seek additional drug approvals following Imaavy's label expansion. | 130d | pharma |
| 90% |
JN
JNJ |
J&J will announce Q3 financial results by early November. | 18d | pharma |
| 90% |
PF
PFE |
Pfizer will hold its Q3 2026 earnings call. | 38d | pharma |
| 90% |
PF
PFE |
Expect ongoing market analysis and debate regarding Pfizer's pipeline and patent cliff strategy. | 38d | pharma |
| 90% |
PF
PFE |
Pfizer will announce Q3 2026 earnings results within the next 60 days. | 7d | pharma |
| 90% |
JN
JNJ |
J&J will announce specific launch plans and initial commercialization strategy for Imaavy in the US. | 39d | pharma |
| 90% |
JN
JNJ |
J&J will announce initial sales figures for Imaavy in Q4 2026 earnings. | 133d | pharma |
| 85% |
JN
JNJ |
J&J will continue oncology pipeline development via Firefly Bio integration. | 130d | pharma |
| 85% |
JN
JNJ |
J&J will integrate Firefly Bio's oncology pipeline. | 130d | pharma |
| 85% |
PF
PFE |
Pfizer will continue to focus on its existing product portfolio, particularly Eliquis, to meet revised revenue targets. | 38d | pharma |
| 85% |
JN
JNJ |
J&J will announce Phase II/III trial initiations for Firefly Bio's KRAS assets within 3 months. | 40d | pharma |
| 85% |
PF
PFE |
Pfizer will launch the XFG-adapted COVID-19 vaccine in the US market. | 40d | pharma |
| 85% |
JN
JNJ |
J&J will disclose further details on the financial impact of the Impella recall in its Q3 2026 earnings call. (SEC 8-K, 2026-08-04; News, 2026-08-27) | 18d | pharma |
| 85% |
JN
JNJ |
J&J will announce a strategic response to the Impella recall, likely including a remediation plan and updated financial guidance. | 41d | pharma |
| 80% |
JN
JNJ |
J&J will report increased Imaavy sales in Q3 earnings. | 7d | pharma |
| 80% |
JN
JNJ |
J&J will file an 8-K detailing the financial impact of the Firefly Bio acquisition within the next 60 days. | 6d | pharma |
| 80% |
JN
JNJ |
J&J will close the Firefly Bio acquisition. | 38d | pharma |
| 80% |
PF
PFE |
Pfizer will continue to emphasize new product performance and pipeline development in upcoming earnings calls and investor communications. | 38d | pharma |
| 80% |
PF
PFE |
Pfizer will provide further updates on its pipeline and patent cliff strategy during Q3 earnings. | 17d | pharma |
| 80% |
JN
JNJ |
J&J will acquire or partner on another oncology asset within six months. | 130d | pharma |
| 80% |
PF
PFE |
Pfizer will continue to ramp new product lines to offset patent cliffs. | 38d | pharma |
| 80% |
PF
PFE |
The company will likely face ongoing investor questions about its pipeline and patent cliff. | 129d | pharma |
| 80% |
PF
PFE |
Pfizer will launch its digital health platform. | 130d | pharma |
| 80% |
JN
JNJ |
J&J will announce Imaavy launch plans within 3 months. | 39d | pharma |
| 80% |
PF
PFE |
Pfizer will secure additional FDA approvals for pipeline assets by year-end. | 74d | pharma |
| 75% |
JN
JNJ |
J&J will announce further clinical trial milestones for Imaavy or Tecvayli within 3 months. | 38d | pharma |
| 75% |
PF
PFE |
Market analysts will scrutinize Q3 results for evidence that new products are sustainably offsetting patent expirations. | 38d | pharma |
| 75% |
JN
JNJ |
J&J will disclose details of the material events from recent 8-K filings in upcoming 10-Q. | 18d | pharma |
| 75% |
PF
PFE |
Pfizer will likely continue to emphasize new product growth to offset patent expirations. | 38d | pharma |
| 75% |
JN
JNJ |
J&J will seek additional oncology drug approvals within 6 months. | 130d | pharma |
| 75% |
PF
PFE |
Pfizer will announce FDA approval or delay for a key oncology asset, validating pipeline progress. | 132d | pharma |
| 70% |
PF
PFE |
Pfizer will probably announce further updates on its key drug portfolio performance, including Eliquis, within the next 3 months. | 38d | pharma |
| 70% |
PF
PFE |
Pfizer will announce a strategic move (M&A or partnership) within the next 2 months to support growth. | 7d | pharma |
| 70% |
JN
JNJ |
J&J will make an additional acquisition or significant investment in the psychedelic or oncology space within 6 months. | 130d | pharma |
| 70% |
PF
PFE |
Pfizer will report Q3 2026 results showing continued revenue growth. | 38d | pharma |
| 70% |
PF
PFE |
Pfizer will announce material progress or setbacks in its oncology pipeline. | 131d | pharma |
| 65% |
JN
JNJ |
J&J will finalize the $5.5 billion talc settlement within 3 months. | 40d | pharma |
| 60% |
JN
JNJ |
J&J will face renewed talc litigation challenges. | 130d | pharma |
| 60% |
PF
PFE |
Pfizer will file additional 8-Ks for material events within the next month. | grading due | pharma |